Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "Ltd."

531 News Found

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr
News | August 11, 2024

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better


Atul Bioscience received EIR from USFDA for Ambernath facility
Drug Approval | August 09, 2024

Atul Bioscience received EIR from USFDA for Ambernath facility

The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations


JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr
News | August 08, 2024

JB Pharma records Q1 FY25 PAT higher by 25% to Rs. 177 Cr

Expect the international business including CDMO business to pick-up in the second half of the financial year


Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr
News | August 06, 2024

Narayana Hrudayalaya posts Q1 FY25 consolidated PAT higher at Rs. 201.37 Cr

Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024


Supriya Lifescience names Dr. Saloni Wagh as MD
People | August 03, 2024

Supriya Lifescience names Dr. Saloni Wagh as MD

Shivani Satish Wagh takes on the role of Joint Managing Director


Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
News | August 03, 2024

Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr

EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin


Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr
News | August 02, 2024

Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr

Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore


Themis Medicare posts Q1 FY25 consolidated PAT higher at Rs. 24.68 Cr
News | July 31, 2024

Themis Medicare posts Q1 FY25 consolidated PAT higher at Rs. 24.68 Cr

Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024


Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar
Drug Approval | July 30, 2024

Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar

Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance


Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr
News | July 26, 2024

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands